Lead Product(s) : Pixatimod
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zucero Therapeutics Announces Promising Covid-19 Virus Laboratory Results
Details : Zucero’s clinical-stage drug candidate pixatimod demonstrates potent antiviral activity against the COVID-19 virus in laboratory studies.
Brand Name : PG545
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 26, 2020
Lead Product(s) : Pixatimod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?